Articles

2022
2021
ARCHIVE

Date

Title

24/01/2022

Invex Therapeutics makes progress ahead of IIH EVOLVE phase three clinical trial

20/12/2021

Invex Therapeutics receives tax rebate for neurological drug research

04/11/2021

Small Caps – Invex Therapeutics chases global registration of Presendin to treat idiopathic intracranial hypertension

20/10/2021

Invex Therapeutics reports busy quarter in Presendin development

27/09/2021

Small Caps – Invex Therapeutics signs major collaboration with Peptron

26/07/2021

Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension

15/06/2021

Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension

27/01/2021

Small Caps – Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder

11/01/2021

COVID-19 Impact on IIH – J Neurol article by Prof Alex Sinclair

23/10/2020

JAMA Ophthalmology Publication – Alex Sinclair